title: A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
abstract: BACKGROUND
  It has been reported that a docetaxel-carboplatin combination as first-line chemotherapy for ovarian cancer showed a level of progression-free survival similar to that of paclitaxel-carboplatin while reducing neurotoxicity and improving quality of life. We investigated the recommended doses of docetaxel-carboplatin in Japanese patients with ovarian cancer and conducted a comparative study of docetaxel-carboplatin versus paclitaxel-carboplatin.
  
  
  METHODS
  Thirty-nine patients with ovarian cancer were enrolled in this study and 38 patients were evaluated. We conducted a dose-escalation study using a docetaxel dose of 70 mg/m(2) and carboplatin AUC 5 and 6. In the comparative study, patients received either docetaxel 70 mg/m(2) and carboplatin AUC 5 or paclitaxel 175 mg/m(2) and carboplatin AUC 5. Progression-free survival, survival rate at 2 years, response rate, toxicity, and quality of life were investigated.
  
  
  RESULTS
  In the dose-finding study, we determined the recommended doses as docetaxel 70 mg/m(2) and carboplatin AUC 5. In the comparative study, the two arms showed similar progression-free survival. Grade 4 neutropenia occurred more frequently in the docetaxel-carboplatin group (84.6%) than in the paclitaxel-carboplatin group (43.8%), while sensory neurotoxicity was less frequent in the docetaxel-carboplatin group (53.8%) than in the paclitaxel-carboplatin (68.8%) group. There were significant differences in the quality-of-life data in favor of docetaxel-carboplatin.
  
  
  CONCLUSIONS
  We determined the recommended doses of docetaxel-carboplatin for Japanese patients with ovarian cancer to be docetaxel 70 mg/m(2) and carboplatin AUC 5. In the comparative study, we suggest that the docetaxel-carboplatin combination is effective and well tolerated as first-line chemotherapy for Japanese patients with ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
authors.forename: Taisuke
authors.initials: T
authors.lastname: Mori
authors.forename: Kenichi
authors.initials: K
authors.lastname: Hosokawa
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Ai
authors.initials: A
authors.lastname: Watanabe
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Haruo
authors.initials: H
authors.lastname: Kuroboshi
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Kato
authors.forename: Jinsuke
authors.initials: J
authors.lastname: Yasuda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujita
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nakata
authors.forename: Hideo
authors.initials: H
authors.lastname: Honjo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007564:Japan; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010865:Pilot Projects; D011788:Quality of Life; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel